Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes

Taspoglutide QW significantly improved pancreatic function in patients with T2D treated with metformin.